MGF
Mechano Growth Factor / IGF-1Ec shorthand; biologically important transcript concept but a highly ambiguous commercial peptide entry
MGF, or mechano growth factor, is one of the most conceptually messy entries in peptide catalogs. In biology, it usually refers to an IGF-1 splice-variant concept linked to the IGF-1Ec transcript and tissue-repair signaling after mechanical stress. In commercial peptide markets, however, MGF often refers to synthetic E-domain peptides or PEGylated analogs that do not map neatly onto a naturally established therapeutic molecule. The repository should therefore classify MGF as an ambiguous / composite entry rather than a single clean drug entity.
Relevant names include mechano growth factor, MGF, IGF-1Ec, and MGF E-domain peptide; some markets also use PEG-MGF for modified versions. The identity section should explicitly separate the endogenous transcript / isoform concept from the synthetic short-peptide products sold under the MGF name. Without that separation, the record becomes misleading.
3. Sequence and structure
There is no single universally standardized “MGF peptide” sequence record that cleanly covers all uses of the term. In serious biology, MGF refers to an IGF-1 splice-variant transcript with a distinct E-domain; in peptide-market practice, it often refers to synthetic 24-amino-acid E-domain peptides or modified versions such as PEG-MGF. The repository should therefore store sequence as a variant-sensitive field and flag any marketed MGF sequence as a specific synthetic construct rather than as the one true endogenous peptide.
Mechanistically, MGF is discussed in relation to tissue response to mechanical overload, muscle repair, satellite-cell biology, and IGF-pathway signaling. The challenge is that the transcript-level biology, mature IGF signaling, and synthetic E-domain peptide claims are not interchangeable. Mechanistic confidence is moderate for the broader biologic concept and lower for many marketed peptide claims.
Most real use cases are experimental: muscle adaptation, regeneration biology, cardiac-repair models, and satellite-cell research. Public claims about dramatic muscle growth, localized hypertrophy, or routine clinical recovery enhancement should be treated as non-approved and often weakly supported. This is a research-concept entry, not an approved therapy entry.
Formal human PK and ADME data are poor for the marketed synthetic MGF-peptide constructs. Much of the literature focuses on cellular or tissue models, splice-variant biology, or localized delivery rather than on mature clinical pharmacology. The repository should be explicit that “MGF pharmacology” often means inferred biology rather than validated therapeutic PK.
There is meaningful preclinical literature around MGF-related biology in muscle and repair, but direct translation into standardized therapeutic peptide efficacy is weak. Importantly, some reviews argue that there is no clear evidence that a stable endogenous 24-amino-acid MGF E-peptide is actually generated in vivo in the way commercial narratives imply. Evidence should therefore be graded cautiously and with ambiguity flags turned on.
Because the marketed forms are poorly standardized and often sold outside regulated channels, safety is undercharacterized. Theoretical concerns include proliferative signaling, off-target growth effects, product contamination, and the usual gray-market manufacturing risks. This entry should carry a high uncertainty warning.
No approved dosing framework exists. Because “MGF” may refer to different molecules altogether, any future dose data must be linked to the exact construct, modification state, and study context.
UNVERIFIED RESEARCHER-REPORTED DOSING INFORMATION
The following dosing information has been compiled from community forums, researcher discussions, and gray-market sources. This information has NOT been verified through peer-reviewed scientific studies or clinical trials. It does NOT constitute medical advice, a prescription, or a recommendation for human use.
This data is presented solely for informational and educational purposes to document what is commonly discussed in research communities. Dosing protocols may be inaccurate, dangerous, or based on anecdotal reports with no scientific validation. Individual responses vary significantly, and unregulated compounds carry inherent risks including contamination, mislabeling, and unknown side effects.
Always consult qualified medical professionals before making any health-related decisions. The repository maintainers assume no liability for the use or misuse of this information.
Researcher-Reported Dosing Protocols
Common Dose Range: 150-400 mcg per injection
Administration Route: Subcutaneous or intramuscular injection
Frequency: 2-3 times per week
Timing: Commonly administered post-workout, in the morning, or 1-2 hours before a workout.
Schedule / Protocol: 4-10 week cycles
Dose Escalation: It is commonly advised to start at a lower dose and gradually increase as needed based on individual tolerance.
Additional Notes: PEG-MGF, a pegylated form with a longer half-life, is often used. Injections are sometimes administered near the specific muscle group being targeted for a localized effect. The timing of administration often aims to mimic the body's natural release of MGF after exercise.
This researcher-reported dosing information was compiled from unverified community sources and does not represent validated scientific or medical guidance.
A mature mainstream clinical-development program for an “MGF peptide” product was not identified in this review. The entry belongs primarily in the preclinical / conceptual-research category.
Not identified as an FDA- or EMA-approved therapeutic product. Best categorized as an ambiguous IGF-1 splice-variant / synthetic E-domain peptide concept with research interest and heavy commercial over-interpretation.
13. References and source quality
Highest-value sources include review articles on IGF-1 splice variants and mechano growth factor, papers studying synthetic MGF E-domain peptides, and critical reviews noting uncertainty about whether a stable endogenous E-peptide exists as marketed. Source quality is mixed but informative, and the disagreement itself is part of the record.
Manufacturing metadata should specify whether a record refers to an unmodified E-domain peptide, PEG-MGF, or another synthetic construct. For this entry, exact construct identity is more important than generic brand-style naming because the commercial MGF label often hides major molecular differences.
Version 0.1 starter entry created March 14, 2026. Evidence basis for this draft: reviews of IGF-1 splice variants and mechano growth factor, experimental MGF E-domain studies, and critical literature highlighting unresolved endogenous-peptide questions.